Abstract CT021: Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC)

Jonathan Riess; Eric B. Haura; Rona Yaeger; Melissa Johnson; Jia Luo; Aparna R. Parikh; Douglas Orr; Salman R. Punekar; Kyriakos Papadopoulos; John H. Strickler; John Powderly; Judy S. Wang; Patricia LoRusso; Alexander I. Spira; Maria Filippou-Frye; Hina Patel; Satwant Lally; Michelle Yang; David S. Hong; Kathryn C. Arbour

doi:10.1158/1538-7445.am2026-ct021

Abstract CT021: Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC)

Cancer Research 2026

View at publisher

Authors: Jonathan Riess, Eric B. Haura, Rona Yaeger, Melissa Johnson, Jia Luo, Aparna R. Parikh, Douglas Orr, Salman R. Punekar, Kyriakos Papadopoulos, John H. Strickler, John Powderly, Judy S. Wang

+8 more

Patricia LoRusso, Alexander I. Spira, Maria Filippou-Frye, Hina Patel, Satwant Lally, Michelle Yang, David S. Hong, Kathryn C. Arbour

DOI: 10.1158/1538-7445.am2026-ct021

Cited by: 4

Abstract

Abstract Background: Patients (pts) with previously treated advanced NSCLC have a high unmet medical need, with a median reported overall survival (OS) of

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research PARP inhibition in cancer therapy

Publication details

Journal / source: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Volume: 86
Issue: 8_Supplement
Pages: CT021–CT021
Publication date: 15 May 2026
Language: EN